Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis

Authors :: Priya Uppuluri
Shakti Singh
Abdullah Alqarihi
Clint S. Schmidt
John P. Hennessey
Michael R. Yeaman
Scott G. Filler
John E. Edwards
Ashraf S. Ibrahim
Source :: Frontiers in Immunology, Uppuluri, P; Singh, S; Alqarihi, A; Schmidt, CS; Jr, HJP; Yeaman, MR; et al.(2018). Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. FRONTIERS IN IMMUNOLOGY, 9. doi: 10.3389/ffimmu.2018.01349. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3r42h3kq, Frontiers in Immunology, Vol 9 (2018)
Publication Year :: 2018
Publisher :: eScholarship, University of California, 2018.
Abstract: A Phase 1b/2a clinical trial of NDV-3A vaccine containing a Candida albicans recombinant Als3 protein formulated with alum protected women

Database :: OpenAIRE
Journal :: Frontiers in Immunology, Uppuluri, P; Singh, S; Alqarihi, A; Schmidt, CS; Jr, HJP; Yeaman, MR; et al.(2018). Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. FRONTIERS IN IMMUNOLOGY, 9. doi: 10.3389/ffimmu.2018.01349. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3r42h3kq, Frontiers in Immunology, Vol 9 (2018)
Accession number :: edsair.doi.dedup.....bfd729b44378d4edfa0e8bd6dd29bbf2
Full Text :: https://doi.org/10.3389/ffimmu.2018.01349.

Full Text Access

Tools